title: Re-admissions for delayed complications after cytoreductive surgery and HIPEC.
abstract: BACKGROUND
  Peritoneal metastasis (PM) is currently treated with the complex procedure of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS + HIPEC). This procedure presents high morbidity and mortality rates, but they have only been examined in the immediate post-operative period. The aim of our study is to present, describe and analyze the post-operative events, secondary to a cytoreductive surgery and HIPEC procedure that occurs after the patients' discharge from the hospital.
  
  
  METHODS
  We examine retrospectively 219 patients who were discharged from our hospital from the initial 230 patients with PM, who were operated on from August 2005 to August 2015 and underwent CRS and HIPEC. Complications are investigated from the patient's discharge date until the 90th post-operative day, and are categorized with the Clavien-Dindo classification.
  
  
  RESULTS
  We identified 17 patients (7.8%) who developed late complications. No major differences in patient characteristics were identified between this group of 17 patients and the rest, apart from a slightly higher PCI (23.5 vs. 22.3). Mean length of stay at the re-admission was 11.7 days. 5 of the patients (29.4%) had to be re-operated on, whereas we found a mortality of 11.8% (2/17 patients). The most common complications involved abdominal abscesses (17.6%), ureteral strictures (17.6%) and enterocutaneous fistulae (17.6%).
  
  
  CONCLUSIONS
  Our study highlights the late complications following CRS plus HIPEC procedures, that occur after the patient's discharge from the hospital, an issue that has not been investigated thoroughly yet and may have serious impact on the post-operative quality of life. The role of adjuvant chemotherapy following CRS and HIPEC procedures in the onset of such complications appears to be important and needs further investigation.
authors.affiliation: a 1st Department of Surgical Oncology , Metaxa Cancer Hospital , Piraeus , Greece ;
authors.forename: J
authors.initials: J
authors.lastname: Spiliotis
authors.affiliation: a 1st Department of Surgical Oncology , Metaxa Cancer Hospital , Piraeus , Greece ;
authors.forename: E O
authors.initials: EO
authors.lastname: Argiriou
authors.affiliation: a 1st Department of Surgical Oncology , Metaxa Cancer Hospital , Piraeus , Greece ;
authors.forename: E
authors.initials: E
authors.lastname: Vafias
authors.affiliation: a 1st Department of Surgical Oncology , Metaxa Cancer Hospital , Piraeus , Greece ;
authors.forename: V
authors.initials: V
authors.lastname: Manou
authors.affiliation: b ICU , Metaxa Cancer Hospital , Piraeus , Greece ;
authors.forename: N
authors.initials: N
authors.lastname: Vaos
authors.affiliation: c Department of Surgery , Hatzikosta General Hospital , Mesolongi , Greece.
authors.forename: A
authors.initials: A
authors.lastname: Datsis
authors.affiliation: a 1st Department of Surgical Oncology , Metaxa Cancer Hospital , Piraeus , Greece ;
authors.forename: E
authors.initials: E
authors.lastname: Efstathiou
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects* / Q000379:methods; D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures / Q000009:adverse effects* / Q000379:methods; D057210:Delayed Diagnosis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010351:Patient Discharge / Q000706:statistics & numerical data; D010359:Patient Readmission / Q000706:statistics & numerical data*; D010534:Peritoneal Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D011183:Postoperative Complications / Q000175:diagnosis / Q000628:therapy; D012189:Retrospective Studies; D018570:Risk Assessment; D015996:Survival Rate; D013997:Time Factors
keywords: HIPEC; Peritoneal metastasis; cytoreductive surgery